Interview: Wendy Adams – General Manager, Galderma Canada
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Galderma is a leading global pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, therapeutic skin care and aesthetic and corrective medical solutions) contribute to maintaining its strong leadership in dermatology. Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and more than 4,000 employees.
Galderma Canada Inc. offers a product portfolio to treat a range of dermatological conditions including: acne, eczema, rosacea, psoriasis and non-melanoma skin cancer.
Strategic brands include:
Tactuo® and Differin® (acne), MetroGel® and Apprilon™ (rosacea), Clobex® (psoriasis), Metvix® (skin cancer), Cetaphil® (therapeutic skin care)
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty…
Hervé Lilliu, General Manager of UCB Canada, describes Canada’s need to support the global pharma-ceutical industry rather than vice versa, and highlights examples of ways in which Canada’s slumbering R&D…
OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc.…
The CEO of OBIO discusses Ontario’s challenges and opportunities in life sciences, highlighting some of the key initiatives that the organization is taking to help local companies bridge the gap…
Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in…
Warren Shapiro, manager of the North American division of Brunel’s life science sector, offers his insights into Canada’s immense human resources capabilities as well as Brunel’s footprint for contract labor…
Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED…
President of Biotalent Canada discusses the advantages of being wholly aligned with the government, why the BioTalent is a necessary link between talent and company, and what this means for…
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an…
The president of Sanofi Pasteur Canada discusses the greatest challenges currently facing vaccine companies in Canada, and the added value that Canada’s R&D framework brings to a vaccine company like…
The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded…
See our Cookie Privacy Policy Here
